The effect of divalent cations on the membrane properties and pharmacokinetics in rat of the lipid A analogue E5531

被引:6
|
作者
Asai, Y
Sano, Y
Kikuchi, K
Iwamoto, K
Watanabe, S
机构
[1] Eisai Co Ltd, Formulat Res Lab, Kawashima, Gifu 5016195, Japan
[2] Eisai Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan
关键词
D O I
10.1211/0022357001773661
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To obtain information on the effects of Ca2+ on the membrane properties of the lipid A analogue E5531, we have determined the aggregate size, zeta potential, membrane fluidity, micropolarity and permeability of the E5531 membrane as a function of Ca2+ levels. Within the molar ratios of [Ca2+]/[E5531] = 1 and 3, Ca2+ increased the zeta potential of the E5531 membrane but had no effect on aggregate size (approximately 20 nm). Within the above ratios, Ca2+ decreased the membrane fluidity, as measured by micropolarity of E5531 and increased the phase transition temperature. The pharmacokinetics in rats for these samples with different membrane fluidity, prepared by changing the pre-dose formulation concentration of Ca2+, was determined and a correlation between membrane fluidity and pharmacokinetics was clearly observed. It thus appears that Ca2+ effects the membrane fluidity of E5531 as well as its pharmacokinetics in rats.
引用
收藏
页码:39 / 45
页数:7
相关论文
共 50 条
  • [11] Suppression of murine endotoxin response by E5531, a novel synthetic lipid A antagonist
    Kobayashi, S
    Kawata, T
    Kimura, A
    Miyamoto, K
    Katayama, K
    Yamatsu, I
    Rossignol, DP
    Christ, WJ
    Kishi, Y
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (11) : 2824 - 2829
  • [12] Characterization of the physicochemical properties of aggregates of the lipid A analog, E5531, prepared by a 'pH-jump method'
    Asai, Y
    Iwamoto, K
    Watanabe, S
    CHEMISTRY AND PHYSICS OF LIPIDS, 1999, 97 (02) : 93 - 104
  • [13] Induction of TNF-α and MnSOD by endotoxin:: effect of E5531, a synthetic non-toxic lipid A analog
    White, JE
    Tsan, MF
    JOURNAL OF ENDOTOXIN RESEARCH, 2000, 6 (04): : 329 - 355
  • [14] A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia
    Bunnell, E
    Lynn, M
    Habet, K
    Neumann, A
    Perdomo, CA
    Friedhoff, LT
    Rogers, SL
    Parrillo, JE
    CRITICAL CARE MEDICINE, 2000, 28 (08) : 2713 - 2720
  • [15] Development of freeze-dried injectable formulation for the novel lipid A analog, E5531
    Asai, Yasuyuki
    E-JOURNAL OF SURFACE SCIENCE AND NANOTECHNOLOGY, 2005, 3 : 169 - 172
  • [16] Development of a dispersal procedure for the lipid A analog E5531 using a 'pH-jump method'
    Asai, Y
    Iwamoto, K
    Watanabe, S
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 170 (01) : 73 - 84
  • [17] E5531, a synthetic non-toxic lipid A derivative blocks the immunobiological activities of lipopolysaccharide
    Kawata, T
    Bristol, JR
    Rossignol, DP
    Rose, JR
    Kobayashi, S
    Yokohama, H
    Ishibashi, A
    Christ, WJ
    Katayama, K
    Yamatsu, I
    Kishi, Y
    BRITISH JOURNAL OF PHARMACOLOGY, 1999, 127 (04) : 853 - 862
  • [18] Development of an injectable formulation for the novel lipid A analog E5531 using a 'pH-jump method'
    Asai, Y
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2004, 124 (12): : 965 - 972
  • [19] Cryoprotective effects of saccharides on the freeze-drying of sonicated vesicles of the novel lipid a analog, E5531
    Asai, Y
    PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2006, 11 (02) : 229 - 233
  • [20] Lipoprotein distribution of a novel endotoxin antagonist, E5531, in plasma from human subjects with various lipid levels
    Wasan, KM
    Strobel, FW
    Parrott, SC
    Lynn, M
    Christ, WJ
    Hawkins, LD
    Rossignol, DP
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (10) : 2562 - 2564